Skye Bioscience, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Skye Bioscience, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($12.75M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($17.62M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($17.62M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($11.10M) | May 8, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($11.10M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($11.10M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.90M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($7.90M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.90M) | Aug 7, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($5.02M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($5.02M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($5.02M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($24.95M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.11M) | Aug 9, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($3.11M) | Nov 7, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($5.17M) | Aug 9, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.17M) | May 10, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($5.17M) | Nov 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.13M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.42M) | Aug 7, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($13.26M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($18.24M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($11.76M) | May 8, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($4.97M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($8.41M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($6.15M) | May 8, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($24.71M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($2.84M) | Aug 9, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($3.10M) | May 10, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.92M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.22M) | Aug 7, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($2.89M) | May 12, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($1.82M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($1.83M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($1.74M) | May 6, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($1.54M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($1.22M) | Aug 6, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($2.21M) | May 7, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($1.50M) | Nov 6, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($1.77M) | Aug 13, 2020 |